Karyopharm Therapeut (KPTI)

$4.23 -0.16 (-3.64%)
Market Cap 37.93M
Revenue (ttm) 145.24M
Net Income (ttm) -76.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52.62%
Debt to Equity Ratio -0.58
Volume 63,700
Avg Vol 73,092
Day's Range N/A - N/A
Shares Out 8.64M
Stochastic %K 0%
Beta 0.24
Analysts Strong Sell
Price Target $21.60

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
celebratelife
celebratelife Jul. 7 at 9:01 PM
$KPTI To: Mansoor Mirza, Garen Bohlin, Deepa Pakianathan, Chen Schor, Barry Greene, Richard Paulson, Christy Oliger, Zhen Su https://x.com/karyowatch/status/1942327797944574310
0 · Reply
Figgies
Figgies Jul. 7 at 4:10 PM
$IONQ let look at some of the most recent Heights deals $PLUG $KPTI
0 · Reply
celebratelife
celebratelife Jul. 6 at 9:13 PM
$KPTI Karm Is A bitch https://x.com/karyowatch/status/1941968658672050235
0 · Reply
celebratelife
celebratelife Jul. 6 at 7:15 PM
$KPTI More on the incompetent or compromised Richard Paulson and the Board https://x.com/karyowatch/status/1941938636141809821
0 · Reply
celebratelife
celebratelife Jul. 6 at 3:11 PM
[Corrected] $KPTI Hiding behind his ugly beard wicked Paulson: https://x.com/karyowatch/status/1941875955426845151
0 · Reply
celebratelife
celebratelife Jul. 5 at 9:36 PM
$KPTI Hiding behind his ugly beard wicked Paulson: https://x.com/karyowatch/status/1941611414478639228
1 · Reply
celebratelife
celebratelife Jul. 5 at 9:17 PM
$KPTI Lousy CEO Paulson, a disgrace to shareholders and a nightmare for himself and the Board who WILL be held liable. https://x.com/karyowatch/status/1941607027966435696
0 · Reply
ssk4stock
ssk4stock Jul. 4 at 5:11 AM
$KPTI All in at 4.23
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 3 at 12:12 PM
$JFBR $KPTI $NVCR $NUKK $PRZO Praying for an end to Israel’s wars soon. 🙏 🌎 https://www.timesofisrael.com/hamas-said-happy-with-us-guarantee-on-talks-to-end-gaza-war-as-ceasefire-momentum-grows/amp/
0 · Reply
celebratelife
celebratelife Jul. 2 at 10:19 PM
$KPTI Don't be surprised if the wicked Board & CEO sell us out for pennies on the $ (KPTI was $375 on their watch) to help the shorts😡. Minor detail: Karma is a Bitch! The wicked Board/Paulson will be held liable. https://x.com/karyowatch/status/1940535571400872343
0 · Reply
Latest News on KPTI
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:05 PM EDT - 6 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Present at the Jefferies Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 4 weeks ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 7 weeks ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025, 9:31 AM EDT - 7 weeks ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 1:39 PM EDT - 7 weeks ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:15 AM EDT - 7 weeks ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025, 4:05 PM EDT - 2 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025, 4:05 PM EDT - 2 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Mar 5, 2025, 12:00 AM EST - 4 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 4 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:05 AM EST - 4 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 19, 2025, 7:30 AM EST - 4 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 13, 2025, 4:30 AM EST - 5 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Feb 12, 2025, 7:00 AM EST - 5 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 13, 2025, 8:30 AM EST - 6 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Jan 2, 2025, 7:00 AM EST - 6 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 9, 2024, 8:00 AM EST - 7 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Dec 3, 2024, 7:00 AM EST - 7 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 8 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 20, 2024, 4:05 PM EST - 8 months ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 18, 2024, 7:00 AM EST - 8 months ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:22 PM EST - 8 months ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 PM EST - 8 months ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:30 AM EST - 8 months ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 8:00 AM EDT - 8 months ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 31, 2024, 7:30 AM EDT - 8 months ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 30, 2024, 4:30 PM EDT - 8 months ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Oct 17, 2024, 10:35 PM EDT - 9 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 23, 2024, 5:00 AM EDT - 10 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Karyopharm to Participate at Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 11 months ago

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 6, 2024, 7:30 AM EDT - 11 months ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

May 2, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Apr 30, 2024, 2:28 PM EDT - 1 year ago

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Mar 6, 2024, 4:05 PM EST - 1 year ago

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 11:26 AM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Feb 29, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Feb 22, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 5, 2024, 12:26 PM EST - 1 year ago

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Jan 8, 2024, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

celebratelife
celebratelife Jul. 7 at 9:01 PM
$KPTI To: Mansoor Mirza, Garen Bohlin, Deepa Pakianathan, Chen Schor, Barry Greene, Richard Paulson, Christy Oliger, Zhen Su https://x.com/karyowatch/status/1942327797944574310
0 · Reply
Figgies
Figgies Jul. 7 at 4:10 PM
$IONQ let look at some of the most recent Heights deals $PLUG $KPTI
0 · Reply
celebratelife
celebratelife Jul. 6 at 9:13 PM
$KPTI Karm Is A bitch https://x.com/karyowatch/status/1941968658672050235
0 · Reply
celebratelife
celebratelife Jul. 6 at 7:15 PM
$KPTI More on the incompetent or compromised Richard Paulson and the Board https://x.com/karyowatch/status/1941938636141809821
0 · Reply
celebratelife
celebratelife Jul. 6 at 3:11 PM
[Corrected] $KPTI Hiding behind his ugly beard wicked Paulson: https://x.com/karyowatch/status/1941875955426845151
0 · Reply
celebratelife
celebratelife Jul. 5 at 9:36 PM
$KPTI Hiding behind his ugly beard wicked Paulson: https://x.com/karyowatch/status/1941611414478639228
1 · Reply
celebratelife
celebratelife Jul. 5 at 9:17 PM
$KPTI Lousy CEO Paulson, a disgrace to shareholders and a nightmare for himself and the Board who WILL be held liable. https://x.com/karyowatch/status/1941607027966435696
0 · Reply
ssk4stock
ssk4stock Jul. 4 at 5:11 AM
$KPTI All in at 4.23
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 3 at 12:12 PM
$JFBR $KPTI $NVCR $NUKK $PRZO Praying for an end to Israel’s wars soon. 🙏 🌎 https://www.timesofisrael.com/hamas-said-happy-with-us-guarantee-on-talks-to-end-gaza-war-as-ceasefire-momentum-grows/amp/
0 · Reply
celebratelife
celebratelife Jul. 2 at 10:19 PM
$KPTI Don't be surprised if the wicked Board & CEO sell us out for pennies on the $ (KPTI was $375 on their watch) to help the shorts😡. Minor detail: Karma is a Bitch! The wicked Board/Paulson will be held liable. https://x.com/karyowatch/status/1940535571400872343
0 · Reply
DoctorDueDiligence
DoctorDueDiligence Jul. 2 at 5:44 AM
$KPTI https://x.com/DueDoctor/status/1940284085441822936
0 · Reply
DoctorDueDiligence
DoctorDueDiligence Jul. 2 at 5:17 AM
$KPTI https://www.reddit.com/r/KPTI/comments/151uan5/open_letter_to_kpti_ceo_richard_paulson/ Wrote this years ago, warning about runway, yet here we are, what is Richard Paulson doing?
0 · Reply
celebratelife
celebratelife Jul. 1 at 8:41 PM
$KPTI Lousy Wicked CEO Richard Paulson Seems As Shorts' Best Friend. Shareholder enemies: wicked inept lousy CEO Richard Paulson + Barry Greene, Mike Mano et al. are a dream team for short sellers. https://x.com/karyowatch/status/1940148401661731037
0 · Reply
longrigger52
longrigger52 Jul. 1 at 12:52 PM
$KPTI crickets
0 · Reply
QaB2i
QaB2i Jul. 1 at 10:39 AM
$EDGM $GALT $JFBR $KPTI $NUKK @sqigfume ain’t got no handle ma eez bin raised by a pack of snapping turtles. Am gettin the car battery and jumping jack flashes.
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 1 at 3:03 AM
$EDGM $GALT $JFBR $NUKK $KPTI Stay focused @squiggleburp ! @mammaburp is not your mother - she is your father!!!! I KNOW THIS BECAUSE my private detectives discovered @race2zero IS YOUR TRUE MOTHER
0 · Reply
celebratelife
celebratelife Jun. 27 at 10:27 PM
$KPTI RICHARD PAULSON IS THE ENEMY OF KPTI SHAREHOLDERS https://x.com/karyowatch/status/1938725817216868809
0 · Reply
DoctorDueDiligence
DoctorDueDiligence Jun. 27 at 1:28 PM
$KPTI I care about fiduciary duty... Does the board? 3 phase 3s.... But right now runway to October 2025... Short of all 3 readouts https://x.com/duedoctor/status/1938588819693199685?s=46
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Jun. 26 at 5:54 PM
$KPTI in
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 24 at 11:43 PM
$JFBR excellent news. The war hungry president of Israel finally listed to @race2zero ‘s hero @donaldjtrumper ! The ceasefire is back on. Bullish for $NVCR $PRZO $KPTI and of course $NVCR & JFBR @squiggleburp 🤫 https://www.wusa9.com/video/news/nation-world/ceasefire-between-israel-and-iran-appears-to-be-holding/65-63c1691b-39da-4083-9840-adae1ee1f412
2 · Reply
nacho217
nacho217 Jun. 24 at 8:42 PM
$KPTI Scam Company, CEO should be already taken into court
1 · Reply
Gius_me
Gius_me Jun. 24 at 5:41 PM
$KPTI so June has almost ended. We haven’t gotten yet myelo phase1 readout, no news on myelo enrollement ph3 completed (but they mentioned July at last), no financial improvement or agreement. Based on earning, we are really closed to bk sanely 🥺😞
1 · Reply